Overview

Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia

Status:
Terminated
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
In this randomized clinical trial (RCT) the investigators are trying to find out whether a low-dose therapy with daily short infusions of urokinase using 10 to 21 doses over a maximum of 30 days is capable of prolonging the survival time without major amputation.
Phase:
Phase 3
Details
Lead Sponsor:
GWT-TUD GmbH